The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 07, 2017

Filed:

Oct. 25, 2013
Applicant:

Institut Gustave Roussy, Villejuif, FR;

Inventors:

Dalil Hannani, Villejuif, FR;

Laurence Zitvogel, Paris, FR;

Caroline Robert, Fontenay-aux-Roses, FR;

Nathalie Chaput-Gras, Paris, FR;

Assignee:

INSTITUT GUSTAVE ROUSSY, Villejuif, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57488 (2013.01); A61K 39/39541 (2013.01); G01N 33/5743 (2013.01); G01N 33/57484 (2013.01); A61K 2039/5158 (2013.01); G01N 2333/7155 (2013.01); G01N 2333/904 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention relates to a method of assessing, predicting or monitoring the sensitivity of a subject having a tumor or cancer to an immunotherapeutic molecule acting on the subject's T cells, to a method of selecting an appropriate treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to the use of corresponding kits. The method of predicting or monitoring the sensitivity of a subject having a tumor to an immunotherapeutic molecule acting on the subject's T cells typically comprises a step a) of determining, in a biological sample from said subject, the expression level of soluble CD25 (sCD25) and, when the expression level is determined, a step b) of comparing at least said expression level to a reference expression level, thereby assessing whether the subject having a tumor is responsive or resistant to the immunotherapeutic molecule.


Find Patent Forward Citations

Loading…